5 Stocks Pushing The Health Care Sector Lower

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

One out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading up 35 points (0.3%) at 14,006 as of Tuesday, Feb. 12, 2013, 12:05 PM ET. The NYSE advances/declines ratio sits at 1,786 issues advancing vs. 1,060 declining with 154 unchanged.

The Health Care sector currently sits up 0.2% versus the S&P 500, which is up 0.1%.

TheStreet Ratings group would like to highlight 5 stocks pushing the sector lower today:

5. Alexion Pharmaceuticals ( ALXN) is one of the companies pushing the Health Care sector lower today. As of noon trading, Alexion Pharmaceuticals is down $1.10 (-1.2%) to $91.20 on average volume Thus far, 910,435 shares of Alexion Pharmaceuticals exchanged hands as compared to its average daily volume of 1.3 million shares. The stock has ranged in price between $91.09-$92.43 after having opened the day at $92.34 as compared to the previous trading day's close of $92.30.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologic therapeutic products in the United States, Europe, Latin America, Japan, and the Asia Pacific. Alexion Pharmaceuticals has a market cap of $18.2 billion and is part of the drugs industry. The company has a P/E ratio of 82.9, above the S&P 500 P/E ratio of 17.7. Shares are down 0.1% year to date as of the close of trading on Monday. Currently there are 15 analysts that rate Alexion Pharmaceuticals a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Alexion Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins, good cash flow from operations and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Alexion Pharmaceuticals Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

4. As of noon trading, Thermo Fisher Scientific ( TMO) is down $0.42 (-0.6%) to $74.33 on light volume Thus far, 322,063 shares of Thermo Fisher Scientific exchanged hands as compared to its average daily volume of 1.9 million shares. The stock has ranged in price between $74.23-$74.96 after having opened the day at $74.74 as compared to the previous trading day's close of $74.75.

Thermo Fisher Scientific, Inc. provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacture, analysis, discovery, and diagnostics. Thermo Fisher Scientific has a market cap of $26.9 billion and is part of the health services industry. The company has a P/E ratio of 21.7, above the S&P 500 P/E ratio of 17.7. Shares are up 16.9% year to date as of the close of trading on Monday. Currently there are 15 analysts that rate Thermo Fisher Scientific a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Thermo Fisher Scientific as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, increase in net income, revenue growth and largely solid financial position with reasonable debt levels by most measures. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Thermo Fisher Scientific Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

3. As of noon trading, HCA Holdings ( HCA) is down $0.62 (-1.7%) to $36.04 on heavy volume Thus far, 11.8 million shares of HCA Holdings exchanged hands as compared to its average daily volume of 4.0 million shares. The stock has ranged in price between $35.85-$36.49 after having opened the day at $36.12 as compared to the previous trading day's close of $36.66.

HCA Holdings, Inc., through its subsidiaries, provides health care services in the United States. HCA Holdings has a market cap of $16.4 billion and is part of the health services industry. The company has a P/E ratio of 10.0, below the S&P 500 P/E ratio of 17.7. Shares are up 23.4% year to date as of the close of trading on Monday. Currently there are 17 analysts that rate HCA Holdings a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates HCA Holdings as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, weak operating cash flow and poor profit margins. Get the full HCA Holdings Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

2. As of noon trading, Humana ( HUM) is down $1.18 (-1.5%) to $79.00 on average volume Thus far, 1.1 million shares of Humana exchanged hands as compared to its average daily volume of 1.9 million shares. The stock has ranged in price between $78.88-$80.63 after having opened the day at $80.40 as compared to the previous trading day's close of $80.18.

Humana Inc. operates as a health care company that offers a range of insurance products and health and wellness services that incorporate an integrated approach to lifelong well-being. Humana has a market cap of $12.9 billion and is part of the health services industry. The company has a P/E ratio of 10.9, below the S&P 500 P/E ratio of 17.7. Shares are up 18.5% year to date as of the close of trading on Monday. Currently there are 15 analysts that rate Humana a buy, no analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates Humana as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, attractive valuation levels, good cash flow from operations and notable return on equity. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full Humana Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

1. As of noon trading, Express Scripts ( ESRX) is down $0.45 (-0.8%) to $54.60 on light volume Thus far, 1.5 million shares of Express Scripts exchanged hands as compared to its average daily volume of 5.8 million shares. The stock has ranged in price between $54.56-$55.29 after having opened the day at $55.01 as compared to the previous trading day's close of $55.05.

Express Scripts Holding Company provides a range of pharmacy benefit management (PBM) services in North America. Express Scripts has a market cap of $45.5 billion and is part of the health services industry. The company has a P/E ratio of 32.2, above the S&P 500 P/E ratio of 17.7. Shares are up 3.2% year to date as of the close of trading on Monday. Currently there are 15 analysts that rate Express Scripts a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Express Scripts as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, reasonable valuation levels, increase in net income and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Express Scripts Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

If you are interested in one of these 4 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

A reminder about TheStreet Ratings group: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

null

More from Markets

Dow Tumbles as Trump Calls Off North Korea Summit

Dow Tumbles as Trump Calls Off North Korea Summit

Jim Cramer: Does Saudi Arabia Think Oil Prices Are Too High?

Jim Cramer: Does Saudi Arabia Think Oil Prices Are Too High?

Stocks Could Easily Crater Into Memorial Day Weekend

Stocks Could Easily Crater Into Memorial Day Weekend

Video: Here Is How Real Estate Investment Trusts Can Boost Your Portfolio

Video: Here Is How Real Estate Investment Trusts Can Boost Your Portfolio

Celgene Shares Rise on Plans to Increase Stock Buybacks

Celgene Shares Rise on Plans to Increase Stock Buybacks